key: cord-0810703-nxfkjtkq authors: Moady, Gassan; Atar, Shaul title: Takotsubo syndrome during the COVID-19 pandemic, state-of -the- art review. date: 2021-05-26 journal: CJC Open DOI: 10.1016/j.cjco.2021.05.011 sha: d543f24d05095f31427fa1913f377652c8229e7a doc_id: 810703 cord_uid: nxfkjtkq The current coronavirus disease 2019 (COVID-19) presents an ongoing medical challenge with multiple organs involvement, including the cardiovascular system. Takotsubo syndrome (TTS) has been described in the context of COVID-19 in two different scenarios: as a direct complication of the infection, and as an indirect outcome secondary to psychological burden of quarantine and social isolation (i.e., stress induced cardiomyopathy). Confirming the diagnosis of TTS in COVID-19 may be challenging due to the limited use of coronary angiography consistent with the recommended guidelines aimed to minimize contact with infected individuals. The use of natriuretic peptide as a diagnostic and prognostic marker in this context may not be reliable since this peptide is already elevated in severe cases of COVID-19 regardless of TTS diagnosis. A relatively high incidence of complications has been reported in these cases, probably related to the severity of the underlying infectious disease. Although quarantine-induced stress cardiomyopathy is a reasonable outcome of the powerful stress during the current pandemic, conflicting results have been reported, and further studies are encouraged to determine the true incidence. The current coronavirus disease 2019 (COVID- 19) presents an ongoing medical challenge with multiple organs involvement, including the cardiovascular system. Takotsubo syndrome (TTS) has been described in the context of COVID-19 in two different scenarios: as a direct complication of the infection, and as an indirect outcome secondary to psychological burden of quarantine and social isolation (i.e., stress induced cardiomyopathy). Confirming the diagnosis of TTS in COVID-19 may be challenging due to the limited use of coronary angiography consistent with the recommended guidelines aimed to minimize contact with infected individuals. The use of natriuretic peptide as a diagnostic and prognostic marker in this context may not be reliable since this peptide is already elevated in severe cases of COVID-19 3 regardless of TTS diagnosis. A relatively high incidence of complications has been reported in these cases, probably related to the severity of the underlying infectious disease. Although quarantine-induced stress cardiomyopathy is a reasonable outcome of the powerful stress during the current pandemic, conflicting results have been reported, and further studies are encouraged to determine the true incidence. We review the literature regarding Takotsubo during COVID-19 as a complication of the infectious disease, and as an indirect outcome of the related stress. The diagnosis is challenging since imaging modalities should be modified to minimize contact with patients. The high rate of complications is probably related to the infectious disease. Quarantine-induced TTS has similar features to other forms of stress related TTS, with incidence that need to be determined in future studies. Takotsubo syndrome (TTS) is a type of acute reversible cardiac dysfunction that mainly affects postmenopausal women, and is usually preceded by physical or emotional stressor (1) (2) (3) . Patients often present with chest pain, ECG changes in the anterior leads, and elevated cardiac biomarkers (2) . Typical echocardiographic findings in most cases are basal hypercontractility and apical ballooning, although other less common forms (i.e., reverse and median types) have been reported (4, 5) . For definitive diagnosis, coronary angiography should be performed to exclude obstructive coronary disease. The pathophysiology of TTS is not fully understood, but it is well established that plasma catecholamines and neuropeptides have a central role 5 (6) (7) (8) . Key pathways involve coronary endothelial dysfunction, various cytokines activation, impaired fatty acid metabolism in cardiac tissue, and multi-vessel spasm leading to demand-supply mismatch and myocardial stunning (9,10). TTS has been described following various physical and emotional stressors such as anger, argument, surgery, natural disasters, grief, happiness, several medications, general anesthesia, and infectious disease (11, 12) . The novel coronavirus disease 2019 outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an ongoing challenge with several medical and economic implications. Multiple cardiovascular complications have been described during SARS-CoV-2 infection including myocardial injury, myocarditis, arrhythmia, and exacerbation of chronic cardiac diseases such as heart failure (13) (14) (15) . In the setting of COVID-19 pandemic, TTS may be encountered as a complication of the acute infection or as an indirect outcome of quarantine-induced stress (stress induced cardiomyopathy). The first cases of COVID-19 associated TTS were reported during the acute phase of the infection with a typical pattern of apical ballooning. Table 1 summarizes the basic characterestics of the cases ( 16-43). HPL, hyperlipidemia; CKD, chronic kidney disease; AF, atrial fibrillation. The type of cardiac troponin assay (T/I) is indicated when available. Most of the reported cases were typical TTS characetrized by apical ballooning and basal hypercontractility. Cases of reverse TTS (characterized by hypercontractility of the apical region and basal hypokinesia) have also been reported (23, 31, 33, 36, 39) . The leading presenting symptom was chest pain with/without dyspnea, and one patient presented with acute ischemic stroke (25) . Of note, several cases were diagnosed based on echocardiography and ECG features during investigation of hemodynamic compromise in critically ill patients with no option for history taking. In most cases, TTS was described during the acute phase, though late onset TTS, 16 days after admission was also reported (19) . Several studies aimed to determine the . Based on these studies, the estimated incidence of TTS complicating SARS-CoV-2 infection is 2-4%, probably more prevalent in critically ill patients, compared to 1-2% among patients presenting with suspected acute coronary syndrome in the general population (9) . While TTS traditionally predominates in postmenopausal women (about 90%), 30% of the currently reported cases are males. TTS has been previously reported in infectious diseases, mainly in bacterial sepsis, and rarely in the setting of viral infections (47,48). The influenza virus is one of the most recognized viruses to cause TTS during the acute infection or following vaccination (49-56). However, the incidence of TTS in the setting of influenza or other viral infections is not known since no studies have been dedicated to investigate the echocardiographic findings in the affected patients. Therfore, it would be difficult to determine whether TTS is more prevalent during COVID-19 than other infectious diseases, or it is simply more investigated in this setting. The pathophysiology of TTS is not fully understood, though several mechanisms have been proposed. Catecholamines, cortisol, and natriuretic peptides (NPs) probably play a central role in the development of the specific type of cardiac stunning in the syndrome by mediating several cardiac processes such as epicardial coronary spasm, microvascular dysfunction and direct myocyte injury (57, 58) . Several findings indicate essential role for catecholamines in TTS including the high plasma levels in the affected patients, and the induction of TTS-like disease following epinephrine or norepinephrin administration (59, 60) . During catecholamines surge, epinephrine triggers β 2 -Adreoreceptor in cardiac tissue to switch from Gs to Gi coupling resulting in apical ballooning (61) . Patients with COVID-19 may be exposed to high catecholamines levels secondary to endogenous excretion as a compensatory mechanism to prevent decompensation, and to exogenous intravenous infusion of adrenaline and noreadrenaline used to maintain adequate blood supply in critically ill patients (62) . High catecholamines levels might act as a double-edged sword by increasing oxygen demand, and inducing vasospasm and direct myocardial injury. The hypothalamic-pituitary-adrenal (HPA) axis is another system that is also activated in severe COVID-19 with subsequent dysregulations in cortisol and adrenocorticotrophic hormone (ACTH) metabolism. During acute illness, activation of HPA axis along with reduced metabolism and decreased breakdown of cortisol contributes to hypercortisolism and hence corticotropin suppression (63) . In the study by Tan et al., levels of cortisol were significantly higher in people with COVID-19 than those without the infection, and survival was halved in people with the highest cortisol levels (64) . Whether hypercortisolemia in COVID-19 is a marker of severe inflammation or a leading cause to impaired immunity and vulnerability for complications is not clear yet. The relation between high cortisol levels and TTS is not well established since TTS has been described in cases of cortisol excess (65) , and also in secondary adrenal deficiency (66) . It is reasonable to assume that activation of the HPA axis during acute illness may mediate TTS by inducing catecholamines secretion. One of the key biomarkers in TTS is N-terminal pro-brain-type natriuretic peptide (NT-proBNP) which is released following increased ventricular wall stress as part of the neurohormonal activation in the setting of heart failure (67) . Similar to other forms of heart failure, NT-proBNP levels in TTS have been shown to correlate with the severity of left ventricle (LV) dysfunction (67) . Compared to patients with ST segment elevation myocardial infarction (STEMI), TTS is associated with higher brain natriuretic peptide (BNP) and lower troponin levels at admission, at peak, and at discharge (68) . This unique biomarker profile of high BNP/Troponin ratio provides a reliable parameter to discriminate TTS from STEMI, particularly when measured at peak (68) . The use of NPs as a diagnostic and prognostic marker in the era of COVID-19 may not be reliable since NPs levels are already elevated in severe cases of COVID-19 regardless of TTS diagnosis (69) . Finally, the release of Interleukin-6, tumor necrosis factor-α, and other pro-infalmmatory cytokines in severe COVID-19 (known as the cytokine storm) might be accompanied by catecholamines surge and further contributes to the development of myocardial stunning (70) . Common ECG findings that may be found in TTS include ST-segment elevation in the precordial leads, anterior T wave inversion, and QT-interval prolongation. Reciprocal ST-segment depression and Q waves are often absent (2, 11) . In the current reported cases, QT prolongation was documented in 8 (27%) patients, though ECG description was not available in two cases. However, it should be noted that patients with COVID-19 are already prone to QT prolongation due to concomitant use of proarrythmic drugs such as quinidine and azithromycin. Cardiac troponin and NT-proBNP levels have been reported to be high in severe COVID-19 reflecting myocardial injury and probably excess mortality (13, 64) . In one study, among 118 patients with laboratory-confirmed COVID-19, those with TTS (5 patients) had higher troponin I and lower BNP levels compared to patients with myocardial injury (defined as troponin I level ≥0.04 ng/ml) but without TTS (45) . As we suggested above, the combination of slight elevation in troponin with excessive NPs levels, commonly seen in TTS, is not applicable as a diagnostic tool in the setting of COVID- The COVID-19 outbreak necessitates special patient care considerations consistent with the need to minimize physical contact. These considerations make history taking somehow limited, particularly in critically ill patients. Use of handled echocardiography devices rather than the large machines is recommended to obtain parameters such as LV function, wall motion abnormailities, and valvular pathologies. One of the more sensitive modalities that was shown to detect early subtle myocardial contractility changes and predicts mortality in TTS is LV strain echocardiography (71) . This modality may help to differentiate TTS from acute coronary syndrome (72) . Here, we suggest a simplified algorithm for managing COVID-19 patients with suspected TTS. In unstable patients, ECG, echocardiography, and angiography when indicated are essential for ruling out obstructive coronary artery disease (CAD). In stable patients and wall motion abnormality (WMA) consistent with takotsubo, the management depends on risk profile. When high risk features present (ongoing chest pain or dyspnea, episodes of ventricular tachycardia, or extremely elevated NPs), cardiac CT is recommended for demonstrating the coronary arteries. Observation and follow-up echocardiography seem reasonable in low-risk patients (without the above-mentioned features). Major complications and outcomes are provided in table 2. About 60% of the patients were on inotropic or ventilatory support. Mechanical circulatory support (V-V ECMO) was provided only in one patient (20) . Thromboembolic events occured in 2 cases (17, 25) , arrhythmia in other 2 cases (38, 42) , and shock in 7 cases (19, 22, 23, 25, 26, 29, 33) . Since sepsis and cytokine storm accompany the clinical course of severe COVID-19, it might be difficult to separate the hemodynamic effects of the underlying sepsis from TTS. Thromboembolic (venous and arterial) events have been reported in COVID-19, particularly in severe cases. In one large registry, major arterial or venous thromboembolic events occured in 35.3% of COVID-19 patients admitted to intensive care unit (ICU) and in 2.6% of hospitalized non-ICU patients, while symptomatic venous thromboembolism was documented in 27% and 2.2% of ICU and non-ICU patients respectively (76) . Septic shock with vasopressors need has been reported in about 70% of COVID-19 patients admitted the ICU (77, 78) . Despite the fact that TTS is described mainly in severe COVID-19, complete recovery was observed in 24 ( 80%) of the cases. The treatment of TTS in COVID-19 should not be different from the usual management of these patients, with emphasis on the underlying disease. Since angiotensin-converting enzyme 2 (ACE2) was recognized early in the pandemic as a potential receptor for SARS-CoV-2 entry, the use of ACE inhibitors was postulated to exhibit deleterious effects in the affected patients. However, recent trial does not support the routine discontinuation of these drugs among patients with mild or moderate COVID-19 (79) . For this reason, the use of ACE inhibitors and beta blockers in TTS in the setting of COVID-19 seems to be reasonable when indicated. Another scenario in which TTS may be encountered in COVID-19 era is related to the subsequent increaes in mental stress, particularly during quarantine and self-isolation. People in quarantine report high prevalence of depression, stress, insomnia and anxiety, brought on by long duration of quarantine, fear of infection, frustration, and inadequate supplies (80). The fact that many of the self-isolated individuals are elderly (in an attempt to protect them from the disease), may directly affect the incidence of TTS since it is predominantly affect elderly women. Three retrospective studies aimed to evaluate the changes in TTS incidence during COVID-19 pandemic. The diagnosis may be challenging in this era since biomarkers are not reliable for this purpose and coronary angiography is often avoided. We suggest performing echocardiogram in patients with COVID-19 using handheld devices to minimze contact with infected patients. The use of coronary angiogram may be appropriate in high risk patients with ongoing chest pain or dyspnea, episodes of ventricular tachycardia, and in those with extremely elevated NPs levels. Otherwise, routine management and repeated echocardiogram are recommended since most reported cases exhibited full cardiac function recovery. Treatment of TTS should be based on managing the underlying disease. The use of ACE inhibitors is appropriate when indicated since these medications were shown to be safe among COVID-19 patients. Stress induced takotsubo is supposed to be a reasonable consequence of this outbreak due to the accompanying stress during self isolation and quarantine, but large studies from different countries are needed to determine the trend in incidence worldwide. The authors have no funding sources to declare. The authors have no conflicts of interest to disclose. Neurohumoral features of myocardial stunning due to sudden emotional stress Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review Characterization of the Myocardial Inflammatory Response in Acute Stress-Induced (Takotsubo) Diagnostic utility of cardiac biomarkers in discriminating Takotsubo cardiomyopathy from acute myocardial infarction Pathophysiology of Takotsubo Syndrome Epidemiology and pathophysiology of Takotsubo syndrome Takotsubo syndrome (stress cardiomyopathy): an intriguing clinical condition in search of its identity Takotsubo syndrome: aetiology, presentation and treatment Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia: JACC Focus Seminar Potential Effects of Coronaviruses on the Cardiovascular System: A Review Stress-Induced Cardiomyopathy Secondary to COVID-19. Case Rep Cardiol COVID-19 Pneumonia, Takotsubo Syndrome, and Left Ventricle Thrombi Takotsubo cardiomyopathy in early term pregnancy: a rare cardiac complication of SARS-CoV-2 infection Takotsubo syndrome as a complication in a critically ill COVID-19 patient. ESC Heart Fail. ESC Heart Fail Reversible cardiac dysfunction in severe COVID-19 infection, mechanisms and case report Takotsubo Cardiomyopathy in a Coronavirus Disease-2019-Positive Patient: A Case Report. A A Pract Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report COVID-19-associated takotsubo cardiomyopathy Apical Takotsubo Cardiomyopathy in a COVID-19 Patient Presenting with Stroke: A Case Report and Pathophysiologic Insights A case of novel coronavirus (COVID-19)-induced viral myocarditis mimicking a Takotsubo cardiomyopathy. HeartRhythm Case Rep Giant inverted T waves in a patient with COVID-19 infection Typical takotsubo syndrome triggered by SARS-CoV-2 infection Takotsubo Syndrome in the Setting of COVID-19 Sindrome Takotsubo in corso di polmonite da SARS-CoV-2: una possibile complicanza cardiovascolare A case of Takotsubo cardiomyopathy with COVID 19 Tako-tsubo syndrome associated with COVID-19 An Interesting Case of COVID-19 Induced Reversed Takotsubo Cardiomyopathy and Insight on Cardiac Biomarkers Takotsubo Syndrome Associated with COVID-19 Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection Stress-Induced Cardiomyopathy Precipitated by COVID-19 and Influenza A Coinfection COVID-19 Presenting as Takotsubo Cardiomyopathy Complicated with Atrial Fibrillation SARS-CoV-2, a novel virus with an unusual cardiac feature: inverted takotsubo syndrome Takotsubo cardiomyopathy triggered by SARS-CoV-2 infection in a critically ill patient Fatal Takotsubo syndrome in critical COVID-19 related pneumonia COVID-19-Associated Stress (Takotsubo) Cardiomyopathy Takotsubo cardiomyopathy in COVID-19: a case report Characteristics and outcome of patients with COVID-19 complicated by Takotsubo cardiomyopathy: case series with literature review Takotsubo Cardiomyopathy in COVID-19 Tako-Tsubo cardiomyopathy after influenza vaccination The Sympathetic Nervous System in the Pathogenesis of Takotsubo Syndrome Neurohumoral features of myocardial stunning due to sudden emotional stress Stress cardiomyopathy after intravenous administration of catecholamines and betareceptor agonists Drug-Induced Takotsubo Cardiomyopathy High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy Catecholamine physiology and its implications in patients with COVID-19 Reduced cortisol metabolism during critical illness Association between high serum total cortisol concentrations and mortality from COVID-19 Takotsubo syndrome secondary to adrenal adenocarcinoma: cortisol as a possible culprit Ampulla (takotsubo) cardiomyopathy caused by secondary adrenal insufficiency in ACTH isolated deficiency N-terminal pro-brain natriuretic protein levels in takotsubo cardiomyopathy Cardiac biomarkers in Takotsubo cardiomyopathy Prognostic value of NT-proBNP in patients with severe COVID-19 Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome Characteristics and Outcomes of Patients With Takotsubo Syndrome: Incremental Prognostic Value of Baseline Left Ventricular Systolic Function Usefulness of left ventricular strain analysis in patients with takotsubo syndrome during acute phase Echocardiographic characteristics of patients with SARS-CoV-2 infection A novel clinical score (InterTAK Diagnostic Score) to differentiate takotsubo syndrome from acute coronary syndrome: results from the International Takotsubo Registry Takotsubo Syndrome Associated With COVID-19: And the InterTAK Diagnosis Score COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State Covid-19 in Critically Ill Patients in the Seattle Region -Case Series Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial